Article
Bromodomains as therapeutic targets in cancer
28 Mar 2013
Abstract excerpt
The malleability of the epigenome has long been recognized as a unique opportunity for therapeutic intervention. Interest in targeting components of the epigenetic machinery for therapeutic gain had initially been aimed at chromatin modifying enzymes. However, advances in medicinal chemistry have now made it possible to exploit protein-protein interactions at the chromatin interface. Bromodomains (BRD) are a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
